Diabetic neuropathy is a debilitating complication of diabetes mellitus, affecting millions worldwide. Epalrestat, an aldose reductase inhibitor, has emerged as a promising therapeutic agent for managing diabetic neuropathy. This review explores the pioneering role of epalrestat in expanding horizons for diabetic neuropathy management. We delve into the pharmacological mechanisms, clinical efficacy, and safety profile of epalrestat, highlighting its potential to ameliorate neuropathic symptoms and improve the quality of life for individuals with diabetes. The comprehensive analysis presented here underscores the significance of epalrestat as a valuable addition to the armamentarium for diabetic neuropathy management.

Diabetic neuropathy, Epalrestat, Aldose reductase inhibitor

IDF Diabetes Atlas. 7th ed. 2015.

Adgaonkar A, Dawange A, Adgaonkar S, Kale V, Shekokar P. Clinical profile of peripheral neuropathy in diabetes mellitus by nerve conduction study. Sch J Appl Med Sci 2014;2(6A): 1973-1977.

Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf

Callaghan B, Cheng H, Stables C, Smith A, Feldman E. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012 Jun;11(6):521-524.

Hosseni A, Abdollahi M. Diabetic neuropathy and oxida- tive stress: therapeutic perspectives. Oxid Med Cell Longev 2012.

Simons A, Orcutt K, Madsen J, Scarbrough P, Spitz D. Oxidative stress in cancer biology and therapy. Dordrecht: Springer; 2012. p. 21-46.

Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005 Jan-Mar;9(1):59-71.

Xu N, Lao Y, Zhang Y, Gillespie D. Akt: A double-edged sword in cell proliferation and genome stability. J Oncol 2012;2012:15. Available from: http://dx.doi.org/10.1155/2012/951724.

Chang F, Lee J, Navolanic P, Steelman L, Shelton J, Blalock W, Franklin R, McCubrey J. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003 Mar;17(3):590-603.

Brunet A, Datta S, Greenberg M. Transcription-dependent and -independent control of neuronal survival by the PI3K– Akt signaling pathway. Curr Opin Neurobiol 2001;11:297-305.